15051756

Source:http://linkedlifedata.com/resource/pubmed/id/15051756

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0005516, umls-concept:C0007102, umls-concept:C0034897, umls-concept:C0681842, umls-concept:C1446468, umls-concept:C1956267
pubmed:issue	9
pubmed:dateCreated	2004-4-30
pubmed:abstractText	The 5-year survival rate of patients with Dukes' B colon cancer is approximately 75%. Identification of the patients at high risk of recurrence in this group would allow better staging and more informed use of adjuvant chemotherapy. In this study, we used DNA chip technology to systematically identify new prognostic markers for tumor relapse in Dukes' B patients.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/15051756-15051754, http://linkedlifedata.com/resource/pubmed/commentcorrection/15051756-17602095
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8309333
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Genetic Markers, http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological
pubmed:status	MEDLINE
pubmed:month	May
pubmed:issn	0732-183X
pubmed:author	pubmed-author:AtkinsDavidD, pubmed-author:JatkoeTimT, pubmed-author:JiangJohnJ, pubmed-author:McLeodHoward LHL, pubmed-author:MutchMatthew GMG, pubmed-author:TalantovDmitriD, pubmed-author:WangYixinY, pubmed-author:ZhangYiY
pubmed:issnType	Print
pubmed:day	1
pubmed:volume	22
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1564-71
pubmed:dateRevised	2007-7-19
pubmed:meshHeading	pubmed-meshheading:15051756-Algorithms, pubmed-meshheading:15051756-Chemotherapy, Adjuvant, pubmed-meshheading:15051756-Colonic Neoplasms, pubmed-meshheading:15051756-Disease-Free Survival, pubmed-meshheading:15051756-Female, pubmed-meshheading:15051756-Gene Expression Profiling, pubmed-meshheading:15051756-Gene Expression Regulation, Neoplastic, pubmed-meshheading:15051756-Genetic Markers, pubmed-meshheading:15051756-Humans, pubmed-meshheading:15051756-Male, pubmed-meshheading:15051756-Middle Aged, pubmed-meshheading:15051756-Neoplasm Recurrence, Local, pubmed-meshheading:15051756-Neoplasm Staging, pubmed-meshheading:15051756-Oligonucleotide Array Sequence Analysis, pubmed-meshheading:15051756-Predictive Value of Tests, pubmed-meshheading:15051756-Prognosis, pubmed-meshheading:15051756-Risk Factors, pubmed-meshheading:15051756-Sensitivity and Specificity, pubmed-meshheading:15051756-Tumor Markers, Biological
pubmed:year	2004
pubmed:articleTitle	Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.
pubmed:affiliation	Veridex, LLC, a Johnson & Johnson Company, 3210 Merryfield Row, San Diego, CA 92121, USA. ywang44@vrxus.jnj.com
pubmed:publicationType	Journal Article, Evaluation Studies